Senate Bill 1848 amends Tennessee Code Annotated, specifically Section 53-11-311, to modify regulations surrounding the use of buprenorphine products for treating substance use disorders. The bill replaces existing language in subdivision (D) of subsection (b)(1) to clarify that buprenorphine mono or buprenorphine without naloxone can be directly administered by healthcare providers within their scope of practice, but it cannot be dispensed in a way that allows for administration away from the dispensing premises.

Additionally, the bill revises subdivision (H) of subsection (c)(2) to restrict the prescription or dispensing of buprenorphine mono or without naloxone, allowing exceptions only for pregnant women, nursing mothers, patients with documented adverse reactions, or when prescribing an injectable mono product. These changes aim to ensure that buprenorphine is used safely and effectively in treatment settings while maintaining strict controls on its distribution. The act will take effect upon becoming law.

Statutes affected:
Introduced: 53-11-311(b)(1), 53-11-311, 53-11-311(c)(2)